As of 2026, is the intrathecal administration of 0.75% hyperbaric bupivacaine (7.5 mg per 1 mL) FDA‑approved and acceptable for anesthesia during total knee arthroscopy (excluding obstetric procedures or total knee arthroplasty)?

Use of 0.75% Hyperbaric Bupivacaine (7.5 mg) for Knee Arthroscopy is NOT FDA-Approved and NOT Acceptable

The FDA explicitly contraindicates 0.75% bupivacaine for intrathecal use outside of surgical procedures requiring high muscle relaxation and prolonged effect, and this concentration carries a black box warning against obstetrical use due to cardiac arrest risk. 1 For knee arthroscopy—a brief, minimally invasive procedure—this concentration is excessive, inappropriate, and potentially dangerous.

FDA Position on 0.75% Bupivacaine

The FDA drug label is unequivocal: "THE 0.75% CONCENTRATION SHOULD BE RESERVED FOR SURGICAL PROCEDURES WHERE A HIGH DEGREE OF MUSCLE RELAXATION AND PROLONGED EFFECT ARE NECESSARY." 1 While the black box warning specifically addresses obstetrical anesthesia (where cardiac arrests and deaths occurred), the underlying concern about systemic toxicity and difficult resuscitation applies to all patient populations. 1

The FDA-approved dosing table does not list 0.75% bupivacaine for any routine spinal anesthesia indication. 1 The label explicitly states that intrathecal 0.75% is reserved for cases demanding extensive motor blockade and duration—criteria that knee arthroscopy does not meet.

Clinical Evidence Against This Dose

Wrong Procedure, Wrong Concentration

Research demonstrates that 7.5 mg of 0.5% hyperbaric bupivacaine is the optimal dose for knee arthroscopy, not 7.5 mg of 0.75%. 2 In a prospective study of 80 patients undergoing diagnostic knee arthroscopy, 7.5 mg of 0.5% hyperbaric bupivacaine achieved adequate unilateral spinal anesthesia in 90% of patients with stable hemodynamics and appropriate motor block. 2 This represents 1.5 mL of 0.5% solution, not 1 mL of 0.75%.

The 0.75% concentration was studied in comparative trials and found to offer no advantage over 0.5% solutions while producing excessive cephalad spread when volumes increased. 3 A 1982 double-blind study concluded: "The use of a 0.75% solution of hyperbaric bupivacaine for spinal anaesthesia did not appear to confer any advantage over the 0.5% solution." 3

Excessive Block for Arthroscopy

Knee arthroscopy requires sensory blockade to approximately T12-L1 with minimal motor block to facilitate same-day discharge. 2 The 0.75% concentration produces complete motor blockade 1, which is unnecessary and counterproductive for outpatient arthroscopy where early mobilization is essential.

Studies on minimum effective anesthetic concentration found that 0.43% bupivacaine (when 10 mg is used) provides complete bilateral lower extremity blockade, and that 0.1% can provide complete anesthesia in some patients. 4 The commercially available 0.75% concentration was deemed "clinically optimal" only when complete bilateral lower extremity blockade is desired—again, not the goal for arthroscopy. 4

Appropriate Alternatives

For knee arthroscopy, use 7.5 mg of 0.5% hyperbaric bupivacaine (1.5 mL) intrathecally. 2 This provides:

• Adequate unilateral sensory and motor block in 85-90% of patients
• Stable hemodynamics
• Appropriate duration for outpatient procedures
• Faster recovery compared to higher concentrations

Alternative evidence-based options include:

• 5-7.5 mg of 0.5% hyperbaric bupivacaine for unilateral block 2
• 10 mg of 0.66% hyperbaric ropivacaine for faster recovery 5
• 12.5 mg isobaric bupivacaine for bilateral block if needed 6

For total knee arthroplasty (TKA)—a more extensive procedure than arthroscopy—guidelines support spinal anesthesia with local anesthetic plus morphine, but do not specify 0.75% concentration. 7 Even for TKA, femoral nerve block or lower concentrations of spinal bupivacaine are preferred. 7

Critical Safety Concerns

The obstetrical guidelines extensively document risks of high-dose intrathecal bupivacaine, including:

• High or total spinal block requiring cardiovascular/respiratory support 8
• Unpredictable block spread with concentrated solutions 8
• Recommendation to limit incremental doses to 2.5 mg when using intrathecal catheters 8

While these guidelines address obstetrical populations, the physiologic risks of excessive intrathecal local anesthetic apply universally. Administering 7.5 mg of 0.75% bupivacaine as a single bolus for arthroscopy violates the principle of using the minimum effective dose.

Common Pitfalls to Avoid

1. Confusing concentration with dose: 7.5 mg can be delivered as 1.5 mL of 0.5% (appropriate) or 1 mL of 0.75% (inappropriate and off-label)
2. Assuming FDA approval based on dose alone: The concentration matters—0.75% is restricted to specific surgical indications
3. Extrapolating from TKA to arthroscopy: These are fundamentally different procedures with different anesthetic requirements
4. Ignoring recovery implications: Excessive motor block from 0.75% solutions delays discharge and increases complications

In summary: Use 7.5 mg of 0.5% hyperbaric bupivacaine (1.5 mL), not 0.75% concentration, for knee arthroscopy. The 0.75% concentration is FDA-restricted to procedures requiring extensive muscle relaxation and is not appropriate for this indication.